Iatrogenic Burden of Atopic Dermatitis

Dermatitis. 2022 Nov-Dec;33(6S):S17-S23. doi: 10.1097/DER.0000000000000799. Epub 2021 Oct 18.

Abstract

The management required for atopic dermatitis (AD) may worsen patient burden, thereby resulting in iatrogenic burden, that is, morbidity caused by medical treatment. We sought to describe the iatrogenic burden of AD and conducted a narrative review of key areas that clinicians can address to minimize it. Clinicians should think strategically about itch trigger avoidance, encourage slow incorporation of lifestyle changes, and emphasize step-up therapy when avoidance becomes too burdensome. Out-of-pocket treatment costs should be incorporated into shared decision making to balance affordability, preference, efficacy, and safety. Polypharmacy should be minimized by eliminating ineffective, nonevidence-based, and redundant therapies while appropriately stepping up to advanced therapy. Clinicians should take adequate time to communicate, the impact of AD on quality of life, and incorporate evidence-based guidelines. The multidimensional nature of AD requires a dynamic approach. Future guidelines should incorporate step-up, step-down, and maintenance approaches to reduce treatment burden and improve quality of life.

Publication types

  • Review

MeSH terms

  • Dermatitis, Atopic* / complications
  • Dermatitis, Atopic* / therapy
  • Humans
  • Iatrogenic Disease
  • Pruritus
  • Quality of Life